

感染制御科学研究センター 研究業績 (2016年)

1. Sueyoshi K, Sumi Y, Inoue Y, Kuroda Y, Ishii K, Nakayama H, Iwabuchi K, Kurishita Y, Shigemitsu H, Hamachi I, Tanaka H. **Fluorescence imaging of ATP in neutrophils from patients with sepsis using organelle-localizable fluorescent chemosensors.** *Ann Intensive Care.* 6(1):64. 2016.
2. Mita T, Culleton R, Takahashi N, Nakamura M, Tsukahara T, Hunja CW, Win ZZ, Htike WW, Marma AS, Dysoley L, Ndounga M, Dzodzomenyo M, Akhwale WS, Kobayashi J, Uemura H, Kaneko A, Hombhanje F, Ferreira MU, Bjorkman A, Endo H, Ohashi J. **Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies.** *Antimicrob Agents Chemother.* 60(6):3340-7. 2016.
3. Kayayama Y, Sekine M, Hishinuma T, Aiba Y, Hiramatsu K. **Complete reconstitution of the VISA phenotype of Mu50 in Vancomycin-Susceptible Staphylococcus aureus.** *Antimicrob Agents Chemother.* 60(6):3730-3743, 2016 2016.
4. Tanaka Y, Amano A, Morisaki M, Sato Y, Sasaki T. **Cellular peptidyl-prolyl cis/trans isomerase Pin1 facilitates replication of feline coronavirus.** *Antiviral Res.* 7;126:1-7 2016.
5. Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M, Shimada N, Suina K, Yoshioka Y, Sasaki S, Moriyama M, Moriyama H, Takahashi K. **Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.** *Biochem Biophys Res Commun.* 473:125-132. 2016.
6. Fudo S*, Yamamoto N*, Nukaga M, Odagiri T, Tashiro M, Hoshino T (*These authors contributed equally to this work). **Two Distinctive Binding Modes of Endonuclease Inhibitors to the N-Terminal Region of Influenza Virus Polymerase Acidic Subunit.** *Biochemistry.* 55:2646-60. 2016.
7. Tada H, Shimizu T, Nagaoka I, Takada H. **Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells.** *Biomed Res* 37: 199-205 2016.

8. Fukui S, Uehara Y, Fujibayashi K, Takahashi O, Hisaoka T, Naito T. **Bacteraemia predictive factors among general medical inpatients: a retrospective cross-sectional survey in a Japanese university hospital.** *BMJ Open* 6: e010527. 2016.
9. Nair VR, Franco LH, Zacharia VM, Khan HS, Stamm CE, You W, Marciano DK, Yagita H, Levine B, Shiloh MU. **Microfold cells actively translocate *Mycobacterium tuberculosis* to initiate infection.** *Cell Rep* 16: 1253-1258 2016.
10. Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T. **Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.** *Clin Nephrol* 85:340-5. 2016.
11. Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N. **Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.** *Exp Hematol.* 44:177-88. 2016.
12. Mita T, Tachibana S, Hashimoto M, Hirai M. **Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites.** *Expert Rev Anti Infect Ther.* 14(1):125-35. 2016.
13. Hashimoto M, Doi M, Kurebayashi N, Furukawa K, Hirawake-Mogi H, Ohmiya Y, Sakurai T, Mita T, Mikoshiba K, Nara T. **Inositol 1,4,5-trisphosphate receptor determines intracellular Ca²⁺ concentration in *Trypanosoma cruzi* throughout its life cycle.** *FEBS Open Bio.* 6:1178-1185. 2016.
14. Hishinuma T, Katayama Y, Matsuo M, Sasaki T, Hiramatsu K. **Complete Genome Sequence of Vancomycin-Intermediate *Staphylococcus aureus* Strain MI (HIP5827).** *Genome Announc.* 17;4(2). 2016.
15. Morita F, Hirai Y, Suzuki K, Uehara Y, Mitsuhashi K, Amano A, Naito T. **Infective endocarditis and Sjögren's syndrome diagnosed simultaneously.** *IDCases* 22: 6-8. 2016.
16. Suzuki K, Hirai Y, Morita F, Uehara Y, Oshima H, Mitsuhashi K, Amano A, Naito T. **A case of**

infective endocarditis along with a ruptured valve caused by *Streptococcus agalactiae* in an immunocompetent man. IDCases 6: 94-96. 2016. 2016.

17. Hu Z, Murakami T, Suzuki K, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Nagaoka I. **Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice.** Int Immunol 28: 245-253 2016.
18. Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Fujimura T, Ikegami T, Nakanaga K, Matsumoto H, Ueno T, Aoki J, Yokomizo T, Konopleva M, Andreeff M, Miida T, Iwabuchi K, Sasai K. **Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells.** Int J Radiat Biol. 92(1):24-34. 2016.
19. Nishizaki Y, Yamagami S, Inoue H, Uehara Y, Kobayashi S, Daida H. **Reactive arthritis caused by urinary tract infection.** Intern Med 55: 1195-1198. 2016.
20. Kamijo M, Wada A, Mineki R, Sakanishi T, Ikeda S. **Prostaglandin E receptor 4 inhibition restores UVB-induced downregulation of ATP2A2/SERCA2 in cultured normal human keratinocytes.** J Dermatol Sci. 81(1):69-71. 2016.
21. Kiatsurayanon C, Niyonsaba F, Chieosilapatham P, Okumura K, Ikeda S, Ogawa H. **Angiogenic peptide (AG)-30/5C activates human keratinocytes to produce cytokines/chemokines and to migrate and proliferate via MrgX receptors.** J Dermatol Sci. 83(3):190-9. 2016.
22. Haga K, Chiba A, Shibuya T, Osada T, Ishikawa D, Kodani T, Nomura O, Watanabe S, Miyake S. **MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis.** J Gastroenterol Hepatol. 31(5):965-72. 2016.
23. Meng L, Bai Z, He S, Mochizuki K, Purushe J, Sun H, Wang J, Yagita H, Mineishi S, Fung H, Yanik GA, Carcchio R, Fan X, Crisalli LM, Hexner EO, Reshef R, Zhang Y, Zhang Y. **The Notch ligand DLL4 defines a capability of human dendritic cells in regulating Th1 and Th17 differentiation.** J Immunol 196: 1070-1080 2016.
24. Suzuki K, Murakami T, Hu Z, Tamura H, Kuwahara-Arai K, Iba T, Nagaoka I. **Human host defense cathelicidin peptide LL-37 enhances the lipopolysaccharide uptake by liver**

sinusoidal endothelial cells without cell activation. J Immunol 196: 1338-1347 2016.

25. Kamijo S, Suzuki M, Hara M, Shimura S, Ochi H, Maruyama N, Matsuda A, Saito H, Nakae S, Suto H, Ichikawa S, Ikeda S, Ogawa H, Okumura K, Takai T. **Subcutaneous allergic sensitization to protease allergen is dependent on mast cells but not IL-33: Distinct mechanisms between subcutaneous and intranasal routes.** J Immunol. 196(9):3559-69. 2016.
26. Shimura S, Takai T, Iida H, Maruyama N, Ochi H, Kamijo S, Nishioka I, Hara M, Matsuda A, Saito H, Nakae S, Ogawa H, Okumura K, Ikeda S. **Epicutaneous allergic sensitization by cooperation between allergen protease activity and mechanical skin barrier damage in mice.** J Invest Dermatol. 136(7):1408-17. 2016.
27. Hayashi E, Chiba A, Tada k, Haga K, Kitagaichi M, Nakajima S, Kusaoi M, Sekiya F, Ogasawara M, Yamaji K, Tamura N, Takasaki Y, Miyake S. **Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis.** J Rheumatol. 43(9):1695-703. 2016.
28. Suzuki A, Uehara Y*, Saita M, Inui A, Isonuma H, Naito T. **Raltegravir and abacavir/lamivudine in Japanese treatment-naïve and treatment-experienced patients with HIV Infection: a 48-week retrospective pilot analysis.** Jpn J Infect Dis 69: 33-38. 2016.
29. Suzuki K, Nagaoka I. **The effect of human host defense peptide LL-37 on endothelial cells.** Juntendo Med J 62: 105-111 2016.
30. Tamura H, Reich J, Nagaoka I. **Bacterial endotoxin assays relevant to host defense peptides.** Juntendo Med J 62: 132-140 2016.
31. Nagaoka I. **Have host defense peptides been acting in innate immunity since the trilobites of the Cambrian period 540 million years ago?** Juntendo Med J 62: 96-97 2016.
32. Hu Z, Nagaoka I. **Modulation of macrophage cell death, pyroptosis by host defense peptide LL-37.** Juntendo Med J 62: 98-104 2016.
33. Pongvongsa T, Nonaka D, Iwagami M, Nakatsu M, Phongmany P, Nishimoto F, Kobayashi J, Hongvanthon B, Brey PT, Moji K, Mita T, Kano S. **Household clustering of asymptomatic**

malaria infections in Xepon district, Savannakhet province, Lao PDR. *Malar J.* 15(1):508. 2016.

34. Kitatani K, Iwabuchi K, Snider A, Riboni L. **Sphingolipids in Inflammation: From Bench to Bedside.** *Mediators of Inflamm.* 2016: 7602526 2016.
35. Iba T, Hamakubo T, Nagaoka I, Sato K, Thachil J. **Physiological levels of pentraxin 3 and albumin attenuate vascular endothelial cell damage Induced by histone H3 in vitro.** *Microcirculation* 23: 240-247 2016.
36. Murakami T, Hu Z, Tamura H, Nagaoka I. **Release mechanism of high mobility group nucleosome binding protein 1 from lipopolysaccharide-stimulated macrophages.** *Mol Med Rep* 13: 3115-3120 2016.
37. Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. **Gut environment-induced intraepithelial autoreactive CD4+ T cells suppress central nervous system autoimmunity via LAG-3.** *Nat Commun.* 20;7:11639. 2016.
38. Hashimoto M, Nara T, Mita T, Mikoshiba K. **Morpholino antisense oligo inhibits trans-splicing of pre-inositol 1,4,5-trisphosphate receptor mRNA of Trypanosoma cruzi and suppresses parasite growth and infectivity.** *Parasitol Int.* 65:175-179. 2016.
39. Takamiya S, Hashimoto M, Mita T, Yokota T, Nakajima Y, Yamakura F, Sugio S, Fujimura T, Ueno T, Yamasaki H. **Bioinformatic identification of cytochrome b5 homologues from the parasitic nematode Ascaris suum and the free-living nematode Caenorhabditis elegans highlights the crucial role of A. suum adult-specific secretory cytochrome b(5) in parasitic adaptation.** *Parasitol Int.* 65(2):113-20. 2016.
40. Takamiya S, Mita T. **Large-scale purification of active liquid-cultured Caenorhabditis elegans using a modified Baermann apparatus.** *Parasitol Int.* 65(5 Pt B):580-583. 2016.
41. Nishizaki N, Nakagawa M, Hara S, Oda H, Kantake M, Obinata K, Uehara Y, Hiramatsu K, Shimizu T. **Effect of PMX-DHP for sepsis due to ESBL-producing Escherichia coli in an extremely low-birthweight infant.** *Pediatr Int* 58: 411-414. 2016.

42. Ikeda N, Shoji H, Suganuma H, Ohkawa N, Kantake M, Murano Y, Sakuraya K, Shimizu T. **Effects of insulin-like growth factor-I during early postnatal period in intrauterine growth-restricted rats.** *Pediatr Int* 58:353-8. 2016.
43. Hoshika Y, Takahashi F, Togo S, Hashimoto M, Nara T, Kobayashi T, Nurwidya F, Kataoka H, Kurihara M, Kobayashi E, Ebana H, Kikkawa M, Ando K, Nishino K, Hino O, Takahashi K, Seyama K. **Haploinsufficiency of the folliculin gene leads to impaired functions of lung fibroblasts in patients with Birt-Hogg-Dubé syndrome.** *Physiol Rep.* 4:e13025. 2016.
44. Inaoka DK, Iida M, Tabuchi T, Honma T, Lee N, Hashimoto S, Matsuoka S, Kuranaga T, Sato K, Shiba T, Sakamoto K, Balogun EO, Suzuki S, Nara T, da Rocha JR, Montanari CA, Tanaka A, Inoue M, Kita K, Harada S. **The Open Form Inducer Approach for Structure-Based Drug Design.** *PLoS One.* 11:e0167078. 2016.
45. Iguchi S, Mizutani T, Hiramatsu K, Kikuchi K. **Rapid Acquisition of Linezolid Resistance in Methicillin-Resistant Staphylococcus aureus: Role of Hypermutation and Homologous Recombination.** *PLoS One.* 16;11(5):e0155512. 2016.
46. Morales J, Hashimoto M, Williams TA, Hirawake-Mogi H, Makiuchi T, Tsubouchi A, Kaga N, Taka H, Fujimura T, Koike M, Mita T, Bringaud F, Concepción JL, Hashimoto T, Embley TM, Nara T. **Differential remodelling of peroxisome function underpins the environmental and metabolic adaptability of diplomonads and kinetoplastids.** *Proc Biol Sci.* 283:20160520. 2016.
47. Hosoda T, Uehara Y*, Matsuda N, Kawase Y, Tanei M, Habu Y, Nakamura A, Tabe Y, Naito T, Ohsaka A. **Performance evaluation of a novel fully automated real-time reverse transcriptase-polymerase chain reaction kit for the detection of norovirus.** *Rinsho Byori* 64: 1347-1352. 2016.
48. Nakayama H, Kurihara H, Morita YS, Kinoshita T, Mauri L, Prinetti A, Sonnino S, Yokoyama N, Ogawa H, Takamori K, Iwabuchi K. **Lipoarabinomannan binding to lactosylceramide in lipid rafts is essential for the phagocytosis of mycobacteria by human neutrophils.** *Sci Signal.* 11;9(449):ra101. 2016.

49. Yatsushiro S, Yamamoto T, Yamamura S, Abe K, Obana E, Nogami T, Hayashi T, Sesei T, Oka H, Okello-Onen J, Odongo-Aginya EI, Alai MA, Olia A, Anywar D, Sakurai M, Palacpac NM, Mita T, Horii T, Baba Y, Kataoka M. **Application of a cell microarray chip system for accurate, highly sensitive, and rapid diagnosis for malaria in Uganda.** Scientific reports. 6:30136. 2016.
50. Honma H, Niikura M, Kobayashi F, Horii T, Mita T, Endo H, Hirai M. **Mutation tendency of mutator Plasmodium berghei with proofreading-deficient DNA polymerase delta.** Scientific reports. 6:36971. 2016.
51. Singh M, Matsuo M, Sasaki T, Morimoto Y, Hishinuma T, Hiramatsu K. **In Vitro Tolerance of A Drug-Naïve Staphylococcus aureus FDA209P towards Vancomycin.** Antimicrob Agents Chemother. 24;61(2). 2017.
52. Chiba A, Tamura N, Yoshikiyo K, Murayama G, Kitagaichi M, Yamaji K, Takasaki Y, Miyake S. **Activation status of mucosal-associated invariant T cells reflects disease activity and pathology of systemic lupus erythematosus.** Arthritis Res Ther. 14;19(1):58. 2017.
53. Inaoka DK, Iida M, Hashimoto S, Tabuchi T, Kuranaga T, Balogun EO, Honma T, Tanaka A, Harada S, Nara T, Kita K, Inoue M. **Design and synthesis of potent substrate-based inhibitors of the Trypanosoma cruzi dihydroorotate dehydrogenase.** Bioorg Med Chem. 25:1465–1470. 2017.
54. Kikuchi K, Matsuda M, Iguchi S, Mizutani T, Hiramatsu 2, Tega-Ishii M, Sansaka K, Negishi K, Shimada K, Umemura J, Notake S, Yanagisawa H, Takahashi H, Yabusaki R, Araoka H, Yoneyama A. **Potential Impact of Rapid Blood Culture Testing for Gram-Positive Bacteremia in Japan with the Verigene Gram-Positive Blood Culture Test.** Can J Infect Dis Med Microbiol. :4896791. 2017.
55. Tan XE, Neoh HM, Looi ML, Chin SF, Cui L, Hiramatsu K, Hussin S, Jamal R. **Activated ADI pathway: the initiator of intermediate vancomycin resistance in Staphylococcus aureus.** Can J Microbiol. 63(3):260-264. 2017.
56. Takehara K, Murakami T, Kuwahara-Arai K, Iba T, Nagaoka I, Sakamoto K. **Evaluation of the**

effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model. *Exp Ther Med.* In press. 2017.

57. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, Hiramatsu K, Watanabe S. **Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis.** *Inflammatory Bowel Diseases.* 23(1):116-125. 2017.
58. Hu Z, Murakami T, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoka I. **Neutrophil extracellular traps (NETs) induces the IL-1 β production by macrophages in combination with lipopolysaccharide.** *Int J Mol Med* 39: 549-558 2017.
59. Sugiyama H, Yoshida I, Ueki M, Tanabe K, Manaka A, Hiramatsu K. **In vitro antibacterial activity of α -methoxyimino acylide derivatives against macrolide-resistant pathogens and mutation analysis in 23S rRNA.** *J Antibiot (Tokyo).* 70(3):264-271. 2017.
60. Miyoshi N, Isogai M, Hiramatsu K, Sasaki T. **Activity of tick antimicrobial peptide from *Ixodes persulcatus* (persulcatusin) against cell membranes of drug-resistant *Staphylococcus aureus*.** *J Antibiot.* 70(2):142-146. 2017.
61. Bautista-López N, Ndao M, Camargo F, Nara T, Jardim A, Annoura T, Hardie D, Borchers C. **Characterization and diagnostic application of *Trypanosoma cruzi* trypomastigote excreted-secreted antigens shed in exosomes released from infected mammalian cells.** *J Clin Microbiol.* 55:744-758. 2017.
62. Tanaka Y, Sato Y, Sasaki T. **Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B.** *J Gen Virol.* 98(2):190-200. 2017.
63. Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, Tachibana SI, Auma M, Ntege EH, Ito D, Takashima E, Palacpac NM, Egwang TG, Onen JO, Kataoka M, Kimura E, Horii T, Tsuboi T. **Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda.** *Malar J.* 16(1):23. 2017.
64. Mizuno M, Noto D, Kaga N, Chiba A, Miyake S. **The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models.** *PLoS One.* 24;12(2):e0173032. 2017.

日本語論文

1. 芳賀慶一, 長田太郎, 渡辺純夫, 千葉麻子, 三宅幸子. **Mucosal Associated Invariant T(MAIT)細胞**. G.I. Research. 24(5):67-68 2016.
2. 能登大介, 三宅幸子. 免疫性神経疾患の基礎科学-免疫学の立場から. Modern Physician. 36(7):613-617 2016.
3. 胡忠双, 長岡功. ピロトーチスによる炎症惹起と抗菌ペプチドによる制御. Thrombosis Medicine 3: 210-215 2016.
4. 能登大介, 三宅幸子. 腸内細菌と免疫疾患. 医学のあゆみ. 258(10):909-914 2016.
5. 能登大介, 三宅幸子. 腸内細菌による免疫調節. 小児科. 57(2):129-136 2016.
6. 平松啓一, 森本ゆふ, 馬場理, 佐々木崇, 菱沼知美, 片山由紀, 松尾美記, 桑原京子, 上原由紀, 五十嵐雅之. バンコマイシン中間耐性 MRSA (VISA) の耐性機構と復帰抗生物質. 日本化学療法学会雑誌 64(3):503-512 2016.
7. 三宅幸子. 免疫性神経疾患と腸管免疫. 最新医学. 71(2):47-53 2016.
8. 能登大介, 三宅幸子. 腸内細菌と免疫応答. 腎臓内科・泌尿器科. 3(3):264-270 2016.
9. 中山仁志, 岩渕和久. スフィンゴ糖脂質の脂質ラフトの構造と機能: ラクトシルセラミドの脂質ラフトを介した自然免疫応答. 生化学 89(1): 62-72. 2017.

著書

1. Croxford JL, Miyake S. **Animal Models for the Study of Neuroimmunological Disease. Neruroimmunological Diseases**. Kusunoki S ed. Springer, Japan, 33-54 (292 頁) 2016.
2. 佐々木崇, 平松啓一 **ブドウ球菌感染症 人獣共通感染症 改訂 3 版** 木村哲、喜田宏編 医薬ジャーナル社 228-235 (550 頁) 2016.
3. 奈良武司. **シャーガス病 (アメリカトリパノソーマ症)**. 人獣共通感染症 改訂 3 版 医薬ジャーナル社、大阪、416-419 (552 頁) 2016.

4. 奈良武司. 原虫症および寄生虫症. 臨床微生物検査ハンドブック第5版. 三輪書店 (印刷中) 2017.
5. Nakayama H, Iwabuchi K. **Molecular mechanisms underlying the immunological activities of glycosphingolipid-enriched lipid rafts in phagocytes.** Reference Modules entitled Chemistry, Molecular Sciences and Chemical Engineering. Elsevier 2017 in press 2017.
6. 奈良武司監訳. **Section 17 原虫および蠕虫感染症：概論、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、1416 (3132 頁) 2017.
7. 奈良武司監訳. **Section 18 原虫感染症、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、1417-1463 (3132 頁) 2017.
8. 奈良武司監訳. **Section 19 蠕虫感染症、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、1464-1490 (3132 頁) 2017.
9. 奈良武司監訳. **245e：寄生虫感染症の診断、246e：寄生虫感染症の治療薬、250e：マラリアおよび Babesia 感染症の血液塗抹アトラス、Section 17 原虫および蠕虫感染症：概論、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、eチャプター (3132 頁) 2017.
10. 奈良武司監訳. **247：アメーバ症および自由生活性アメーバ感染症、248：マラリア、249：Babesia 感染症、251：リーシュマニア症、252：Chagas 病およびアフリカトリパノソーマ症、254：腸管寄生原虫感染症とトリコモナス症、Section 17 原虫および蠕虫感染症：概論、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、1417-1463 (3132 頁) 2017.
11. 奈良武司監訳. **255e：蠕虫感染総論、Section 19 蠕虫感染症、Part 8 感染症** ハリソン内科学第5版 福井次矢、黒川清監修、メディカル・サイエンス・インターナショナル、東京、eチャプター (3132 頁) 2017.

12. 奈良武司監訳. 259 : 住血吸虫症およびその他の吸虫感染症、260 : 条虫感染症、
Section 19 蠕虫感染症、Part 8 感染症 ハリソン内科学第 5 版 福井次矢、黒川清監修、
メディカル・サイエンス・インターナショナル、東京、1478-1490 (3132 頁) 2017.

特許

1. 特許出願人：学校法人順天堂
発明者：山本典生
抗インフルエンザウイルス剤
特許公開日：2016 年 10 月 28 日
特許 6028968 号